Table 3 Summary of antimycobacterial therapy over more than 10 years of follow-up
Date | Event | Antimycobacterial therapy | Duration |
|---|---|---|---|
2011 | Disseminated Mycobacterium szulgai Mycobacterium isolation INH toxicity Suspected AZM intolerance | INH, RIF, EMB and AZM RIF, EMB and AZM RIF, EMB and MXF | 16 Months 11 Months 4 Months 1 Months |
2014 | Disseminated MAC Mycobacterium isolation Antibiogram available Vertebral lesions worsening Vertebral lesions improvement Simplified treatment | RIF, EMB and MXF RIF, EMB and AZM RIF, EMB, AZM, AMK and CLO RIF, EMB, AZM and CLO RIF, EMB, AZM | 44 Months 2 Months 5 Months 5 Months 3 Months 29 Months |
2018 | Suspected relapse/reinfection of dNTM Thoracic lymphadenopathies/pneumonia | RIF, EMB and AZM | 7 Months 7 Months |
2020 | Suspected relapse/reinfection of dNTM Patient’s decision Lymphadenopathies/splenic and skeletal lesions recurrence Lymphadenopathies/splenic and skeletal lesions improvement | RIF, EMB, AZM (discontinuous) RIF, EMB, AZM, AMK and CLO RIF, EMB, AZM and CLO RIF, EMB, AZM | 40 Months 2 Weeks 5 Months 23 Months 10 Months (ongoing) |